DNA定量分析在非小细胞肺癌化疗中的价值  

Value of DNA quantitative analysis in planning of chemotherapy of non small cell lung cancer

作　　者：郭纪全[1] 陈正贤[1] 王随照[1] 

机构地区：[1]广东省人民医院呼吸科,广东广州510080

出　　处：《中国癌症杂志》2000年第3期229-231,共3页China Oncology

摘　　要：目的 :探讨DNA定量分析在非小细胞肺癌化疗中的作用。方法 :90例非小细胞肺癌患者应用MVC方案治疗 ,化疗前采用流式细胞仪测定其细胞DNA含量。结果 :DNA含量为异倍体者 49例 ,二倍体 41例 ,高S期百分比者 31例 ,低S期百分比者 5 9例 ,化疗总有效率为 46 7% ,其中异倍体肿瘤化疗有效率为 5 7 1% ,二倍体者有效率为 34 1% ,两者相比较差异具有显著性 (P <0 0 5 ) ;高S期百分比者化疗有效率为 74 2 % ,低S期百分比者有效率为 32 2 % ,两者相比较差异同样具有显著性 (P <0 0 0 5 )。结论 :非小细胞肺癌异倍体者或高S期百分比者对化疗更为敏感 。Purpose:To assess the value of DNA quantitative analysis in the planning of chemotherapy of non small cell lung cancer.Methods:90 cases of non small cell lung cancer were analyzed by flow cytometry and treated by MVC regimen. Results:41 tumors were aneupliod and 49 dipliod, 31 tumors with high S phase fraction and 59 low S phase fraction. Overall response rate (RR) was 46.7%, in aneuploid patients, the RR was 57.1%, and in diploid patients it was 34.1%, the RRs in patients with high and low S phase fraction were 74.2% and 32.2% respectively. Comparison showed that aneuploid tumors and tumors with high S phase fraction appeared to respond better to chemotherapy than diploid tumors and tumors with low S phase fraction, the differences were significant ( P <0 05). Conclusions:These findings indicate that non small cell lung cancer with aneuploidy or high S phase fraction is more sensitive to chemotherapy, the pretreatment DNA quantitative analysis may be useful in selecting high risk patients who might benifit from chemotherapy.

关 键 词：非小细胞肺癌 流式细胞仪 DNA含量 药物疗法 

分 类 号：R734.2[医药卫生—肿瘤] R730.43[医药卫生—临床医学]